摘要 |
This application provides a method for treating a human subject afflicted with Parkinson's disease (PD) with a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and a pharmaceutically acceptable carrier, comprising the steps of: (i) obtaining a biological sample comprising a genome from the human subject afflicted with Parkinson's disease; (ii) assaying the DNA or RNA of the biological sample from the human subject using a probe or a primer, to determine the diploid genotype of the human subject at single nucleotide polymorphism (SNP) rs1076560 or rs2283265; (iii) identifying the human subject as a predicted responder to rasagiline if the diploid genotype is CC at rs1076560, CC at rs2283265, or CC at both rs1076560 and rs2283265; and (iv) administering the pharmaceutical composition comprising rasagiline and a pharmaceutically acceptable carrier to the human subject if the human subject is identified as a predicted responder to rasagiline. |
申请人 |
TEVA PHARMACEUTICAL INDUSTRIES LTD. |
发明人 |
LEVY, JOSEPH;TCHELET, AMIR;GROSSMAN, IRIS;EYAL, ELI;OFRA, BARNETT;COLLINSON, MAUREEN SHANNON;KENNEDY, JAMES LOWERY;KNIGHT, JOANNE;LANG, ANTHONY EDWARD;MASELLIS, MARIO |